| pubmed-article:15133484 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15133484 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:15133484 | lifeskim:mentions | umls-concept:C0026764 | lld:lifeskim |
| pubmed-article:15133484 | lifeskim:mentions | umls-concept:C0038250 | lld:lifeskim |
| pubmed-article:15133484 | lifeskim:mentions | umls-concept:C0229664 | lld:lifeskim |
| pubmed-article:15133484 | lifeskim:mentions | umls-concept:C0010583 | lld:lifeskim |
| pubmed-article:15133484 | lifeskim:mentions | umls-concept:C0015133 | lld:lifeskim |
| pubmed-article:15133484 | lifeskim:mentions | umls-concept:C0300926 | lld:lifeskim |
| pubmed-article:15133484 | lifeskim:mentions | umls-concept:C0600688 | lld:lifeskim |
| pubmed-article:15133484 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:15133484 | pubmed:dateCreated | 2004-6-21 | lld:pubmed |
| pubmed-article:15133484 | pubmed:abstractText | The purpose of the study was to examine the yield of CD34(+) cells, response rates, and toxicity of high-dose cyclophosphamide with or without etoposide in patients with multiple myeloma. In total, 77 myeloma patients received either cyclophosphamide 4.5 g/m(2) (n=28) alone or with etoposide 2 g/m(2) (n=49) in a nonrandomized manner, followed by G-CSF 10 microg/kg/day for the purpose of stem cell mobilization. The effects of various factors on CD34(+) cell yield, response rate and engraftment were explored. A median of 22.39 x 10(6) CD34(+) cells/kg were collected on the first day of leukapheresis (range 0.59-114.71 x 10(6)/kg) in 71 (92%) of patients. Greater marrow plasma cell infiltration (P=0.02) or prior radiation therapy (P=0.02) adversely affected CD34(+) cell yield. In total, 45% of patients receiving cyclophosphamide and 56% of those receiving cyclophosphamide/etoposide had at least a minimum response by EBMT criteria. In all, 25% of patients who received cyclophosphamide alone vs 75.5% of patients who received combined chemotherapy required hospitalization mainly for treatment of neutropenic fever. Cyclophosphamide alone is associated with impressive CD34(+) cell yields and clear antimyeloma activity. The addition of etoposide resulted in increased toxicity without significant improvement in CD34(+) cell yield or response rates. | lld:pubmed |
| pubmed-article:15133484 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15133484 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15133484 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15133484 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15133484 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15133484 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15133484 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15133484 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15133484 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:15133484 | pubmed:issn | 0268-3369 | lld:pubmed |
| pubmed-article:15133484 | pubmed:author | pubmed-author:GutDD | lld:pubmed |
| pubmed-article:15133484 | pubmed:author | pubmed-author:TricotGG | lld:pubmed |
| pubmed-article:15133484 | pubmed:author | pubmed-author:Cottler-FoxMM | lld:pubmed |
| pubmed-article:15133484 | pubmed:author | pubmed-author:HeymanMM | lld:pubmed |
| pubmed-article:15133484 | pubmed:author | pubmed-author:FassasAA | lld:pubmed |
| pubmed-article:15133484 | pubmed:author | pubmed-author:RapoportA PAP | lld:pubmed |
| pubmed-article:15133484 | pubmed:author | pubmed-author:TakebeNN | lld:pubmed |
| pubmed-article:15133484 | pubmed:author | pubmed-author:MeisenbergBB | lld:pubmed |
| pubmed-article:15133484 | pubmed:author | pubmed-author:Sarkodee-Adoo... | lld:pubmed |
| pubmed-article:15133484 | pubmed:author | pubmed-author:FANDS BSB | lld:pubmed |
| pubmed-article:15133484 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15133484 | pubmed:volume | 34 | lld:pubmed |
| pubmed-article:15133484 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15133484 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15133484 | pubmed:pagination | 69-76 | lld:pubmed |
| pubmed-article:15133484 | pubmed:dateRevised | 2006-4-24 | lld:pubmed |
| pubmed-article:15133484 | pubmed:meshHeading | pubmed-meshheading:15133484... | lld:pubmed |
| pubmed-article:15133484 | pubmed:meshHeading | pubmed-meshheading:15133484... | lld:pubmed |
| pubmed-article:15133484 | pubmed:meshHeading | pubmed-meshheading:15133484... | lld:pubmed |
| pubmed-article:15133484 | pubmed:meshHeading | pubmed-meshheading:15133484... | lld:pubmed |
| pubmed-article:15133484 | pubmed:meshHeading | pubmed-meshheading:15133484... | lld:pubmed |
| pubmed-article:15133484 | pubmed:meshHeading | pubmed-meshheading:15133484... | lld:pubmed |
| pubmed-article:15133484 | pubmed:meshHeading | pubmed-meshheading:15133484... | lld:pubmed |
| pubmed-article:15133484 | pubmed:meshHeading | pubmed-meshheading:15133484... | lld:pubmed |
| pubmed-article:15133484 | pubmed:meshHeading | pubmed-meshheading:15133484... | lld:pubmed |
| pubmed-article:15133484 | pubmed:meshHeading | pubmed-meshheading:15133484... | lld:pubmed |
| pubmed-article:15133484 | pubmed:meshHeading | pubmed-meshheading:15133484... | lld:pubmed |
| pubmed-article:15133484 | pubmed:meshHeading | pubmed-meshheading:15133484... | lld:pubmed |
| pubmed-article:15133484 | pubmed:meshHeading | pubmed-meshheading:15133484... | lld:pubmed |
| pubmed-article:15133484 | pubmed:meshHeading | pubmed-meshheading:15133484... | lld:pubmed |
| pubmed-article:15133484 | pubmed:meshHeading | pubmed-meshheading:15133484... | lld:pubmed |
| pubmed-article:15133484 | pubmed:meshHeading | pubmed-meshheading:15133484... | lld:pubmed |
| pubmed-article:15133484 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15133484 | pubmed:articleTitle | High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: efficacy and toxicity. | lld:pubmed |
| pubmed-article:15133484 | pubmed:affiliation | Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA. igojo@umm.edu | lld:pubmed |
| pubmed-article:15133484 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15133484 | pubmed:publicationType | Clinical Trial | lld:pubmed |
